Title:
METHOD FOR PREDICTING ANTITUMOR EFFICACY OF HSP90 INHIBITOR IN CANCER TREATMENT
Document Type and Number:
WIPO Patent Application WO/2015/093291
Kind Code:
A1
Abstract:
A method for determining the sensitivity of a tumor to an Hsp90 inhibitor by measuring the Akt phosphorylation level or the ERK phosphorylation level in tumor tissue from a patient.
Inventors:
FUKUDA TSUYOSHI (JP)
MIYAZAKI OSAMU (JP)
MASUDA KUNIKO (JP)
OKAMOTO KAZUYA (JP)
MIYAZAKI OSAMU (JP)
MASUDA KUNIKO (JP)
OKAMOTO KAZUYA (JP)
Application Number:
PCT/JP2014/081968
Publication Date:
June 25, 2015
Filing Date:
December 03, 2014
Export Citation:
Assignee:
NIPPON KAYAKU KK (JP)
International Classes:
C12Q1/48; G01N33/574
Domestic Patent References:
| WO2013009655A2 | 2013-01-17 | |||
| WO2013074594A1 | 2013-05-23 | |||
| WO2006095783A1 | 2006-09-14 | |||
| WO2006095783A1 | 2006-09-14 | |||
| WO2009023211A1 | 2009-02-19 | |||
| WO2007134678A2 | 2007-11-29 | |||
| WO2011060328A1 | 2011-05-19 | |||
| WO2007139952A2 | 2007-12-06 |
Foreign References:
| JP2012500013A | 2012-01-05 | |||
| JP2008538750A | 2008-11-06 | |||
| JP2013510585A | 2013-03-28 | |||
| JP2012500013A | 2012-01-05 |
Other References:
"Activity of a Specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 1038 - 42
"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, 2004, pages 2129 - 39
"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", THE LANCET ONCOLOGY, vol. 12, 2011, pages 735 - 42
"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 783 - 92
"Lapatinib plus capecitabine for HER2-positive advanced breast cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, 2006, pages 2733 - 43
"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, 2010, pages 1693 - 703
"Hsp90 inhibitors as novel cancer chemotherapeutic agents", TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4, 2002, pages 55 - 61
"Roles of the RatfMEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging", AGING, vol. 3, 2011, pages 192 - 222
"Targeting the Raf-MEK-ERK mitogen-actiated protein kinase cascade for the treatment of cancer", ONCOGENE, vol. 26, 2007, pages 3291 - 310
See also references of EP 3086119A4
"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, 2004, pages 2129 - 39
"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", THE LANCET ONCOLOGY, vol. 12, 2011, pages 735 - 42
"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, 2001, pages 783 - 92
"Lapatinib plus capecitabine for HER2-positive advanced breast cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, 2006, pages 2733 - 43
"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, 2010, pages 1693 - 703
"Hsp90 inhibitors as novel cancer chemotherapeutic agents", TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4, 2002, pages 55 - 61
"Roles of the RatfMEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging", AGING, vol. 3, 2011, pages 192 - 222
"Targeting the Raf-MEK-ERK mitogen-actiated protein kinase cascade for the treatment of cancer", ONCOGENE, vol. 26, 2007, pages 3291 - 310
See also references of EP 3086119A4
Attorney, Agent or Firm:
HIROTA, Koichi et al. (JP)
Koichi Hirota (JP)
Koichi Hirota (JP)
Download PDF: